Literature DB >> 9163286

Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial.

J P Cello1, E J Ring, E W Olcott, J Koch, R Gordon, J Sandhu, D R Morgan, J W Ostroff, D C Rockey, P Bacchetti, J LaBerge, J R Lake, K Somberg, C Doherty, M Davila, K McQuaid, S D Wall.   

Abstract

BACKGROUND: Hemorrhage from esophageal varices remains a substantial management problem. Endoscopic sclerotherapy was preferred for more than a decade, but fluoroscopically placed intrahepatic portosystemic stents have recently been used with increasing frequency.
OBJECTIVE: To compare sclerotherapy with transjugular intrahepatic portosystemic shunt (TIPS) in patients with bleeding from esophageal varices.
DESIGN: Randomized, controlled clinical trial.
SETTING: Three teaching hospitals. PATIENTS: 49 adults hospitalized with acute variceal hemorrhage from November 1991 to December 1995: 25 assigned to sclerotherapy and 24 assigned to TIPS. INTERVENTION: Patients assigned to repeated sclerotherapy had the procedure weekly. In those assigned to TIPS, an expandable mesh stent was fluoroscopically placed between an intrahepatic portal vein and an adjacent hepatic vein. MEASUREMENTS: Pretreatment measures included demographic and laboratory data. Postrandomization data included index hospitalization survival, duration of follow-up, successful obliteration of varices, rebleeding from varices, number of variceal rebleeding events, total days of hospitalization for variceal bleeding, blood transfusion requirements after randomization, prevalence of encephalopathy, and total health care costs.
RESULTS: Mean follow-up (+/-SE) was 567 +/- 104 days in the sclerotherapy group and 575 +/- 109 days in the TIPS group. Varices were obliterated more reliably by TIPS than by sclerotherapy (P < 0.001). Patients having TIPS were significantly less likely to rebleed from esophageal varices than patients receiving sclerotherapy (3 of 24 compared with 12 of 25; P = 0.012). No other follow-up measures differed significantly between groups. A trend toward improved survival, which was not statistically significant, was noted in the TIPS group (hazard ratio, 0.53 [95% CI, 0.18 to 1.5]).
CONCLUSIONS: In obliterating varices and reducing rebleeding events from esophageal varies, TIPS was more effective than sclerotherapy. However, TIPS did not decrease morbidity after randomization or improve health care costs. It seemed to produce better survival, but the increase in survival was not statistically significant.

Entities:  

Mesh:

Year:  1997        PMID: 9163286     DOI: 10.7326/0003-4819-126-11-199706010-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  37 in total

Review 1.  TIPSS 10 years on.

Authors:  R Jalan; H F Lui; D N Redhead; P C Hayes
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

2.  UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology.

Authors:  R Jalan; P C Hayes
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

3.  Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial.

Authors:  G Pomier-Layrargues; J P Villeneuve; M Deschênes; B Bui; P Perreault; D Fenyves; B Willems; D Marleau; M Bilodeau; M Lafortune; M P Dufresne
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 4.  Transjugular portosystemic stent shunt in treatment of liver diseases.

Authors:  M Schepke; T Sauerbruch
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 5.  Current status of transjugular intrahepatic portosystemic shunts.

Authors:  N H Patel; N Chalasani; R M Jindal
Journal:  Postgrad Med J       Date:  1998-12       Impact factor: 2.401

6.  Transjugular intrahepatic portosystemic shunts in patients with hepatic malignancy.

Authors:  Michael J Wallace; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 7.  Current use of transjugular intrahepatic portosystemic shunts.

Authors:  Timothy M McCashland
Journal:  Curr Gastroenterol Rep       Date:  2003-02

8.  Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding.

Authors:  Basile Njei; Thomas R McCarty; Loren Laine
Journal:  J Gastroenterol Hepatol       Date:  2017-04       Impact factor: 4.029

9.  Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.

Authors:  Ming Bai; Chuang-Ye He; Xing-Shun Qi; Zhan-Xin Yin; Jian-Hong Wang; Wen-Gang Guo; Jing Niu; Jie-Lai Xia; Zhuo-Li Zhang; Andrew C Larson; Kai-Chun Wu; Dai-Ming Fan; Guo-Hong Han
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

10.  Interventional radiology in the management of portal hypertension.

Authors:  Sundeep J Punamiya
Journal:  Indian J Radiol Imaging       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.